利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

179 条记录 (耗时 0.053 秒)

    Compositions and Methods for Treating and Diagnosing Cancer
    82.
    发明申请
    Compositions and Methods for Treating and Diagnosing Cancer 有权
    治疗和诊断癌症的组成和方法

    公开(公告)号：US20150165024A1

    公开(公告)日：2015-06-18

    申请号：US14504680

    申请日：2014-10-02

    申请人： OncoMed Pharmaceuticals, Inc.

    发明人： Austin L. GURNEY

    IPC分类号： A61K39/395 ,  A61K45/06 ,  C07K16/18

    CPC分类号： A61K39/39558 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K14/723 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/76 ,  C07K2319/30

    摘要： The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cells. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.

    摘要翻译： 本发明涉及用于表征，诊断和治疗癌症的组合物和方法。 特别地，本发明将LGR5鉴定为在实体瘤干细胞中过表达的蛋白质。 本发明进一步鉴定了RSPO1和LGR5之间的相互作用，作为β-连环蛋白信号传导活化的替代途径。 在某些实施方案中，本发明提供了通过LGR蛋白破坏功能性信号传导的生物分子，包括在某些实施方案中抑制一种或多种RSPO蛋白与一种或多种LGR蛋白如LGR5之间相互作用的分子。 在某些实施方案中，本发明提供了治疗癌症的方法，包括破坏功能性LGR信号并抑制包含固体肿瘤干细胞的实体瘤的生长。

    Compositions and Methods for Diagnosing and Treating Cancer
    88.
    发明申请
    Compositions and Methods for Diagnosing and Treating Cancer 有权
    诊断和治疗癌症的组成和方法

    公开(公告)号：US20140349399A1

    公开(公告)日：2014-11-27

    申请号：US14266998

    申请日：2014-05-01

    申请人： OncoMed Pharmaceuticals, Inc.

    发明人： Austin GURNEY ,  John Lewicki ,  Sanjeev Satyal ,  Timothy Hoey

    IPC分类号： C07K16/28 ,  C07K16/18

    CPC分类号： C07K14/705 ,  A61K38/00 ,  A61K45/06 ,  A61K2039/505 ,  C07K14/723 ,  C07K16/00 ,  C07K16/18 ,  C07K16/28 ,  C07K2319/30 ,  C07K2319/33 ,  G01N33/57423 ,  G01N33/57492

    摘要： The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth.

    摘要翻译： 本发明涉及用于表征，诊断和治疗癌症的组合物和方法。 特别地，本发明提供了用于癌症的诊断，表征，预后和治疗以及特异性靶向癌症干细胞的方法和方法。 本发明提供了包含抑制肿瘤细胞生长的人FZD受体的细胞外结构域的可溶性FZD受体。 本发明还提供一种可溶性受体，其包含结合人FZD受体的配体的人FZD受体的Fri结构域，并且所述可溶性受体能够抑制肿瘤生长。 本发明还提供一种治疗癌症的方法，其包括以有效抑制肿瘤生长的量施用包含例如人FZD受体的细胞外结构域或人FZD受体的Fri结构域的可溶性FZD受体。